Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients

Clinical Therapeutics

Volumn 19, Issue 3, 1997, Pages 471-480

  Murray, Patricia A ^a,d   Koletar, Susan L ^b   Mallegol, Irma ^c   Wu, Jane ^c   Moskovitz, Bruce L ^c  

^a Private Practice   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d NONE   (United States)

Author keywords

Clotrimazole; HIV AIDS; Itraconazole; Oropharyngeal candidiasis

Indexed keywords

CLOTRIMAZOLE; ITRACONAZOLE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG SOLUTION; ERYTHEMA; FEMALE; FOLLOW UP; FUNGUS CULTURE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MOUTH LESION; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; OROPHARYNX; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SYMPTOM; THRUSH; VOMITING;

EID: 0030861779     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80131-2     Document Type: Article

References (24)

1. Greenspan D. Treatment of oropharyngeal candidiasis in HIV-positive patients. J Am Acad Dermatol. 1994;31(3 Pt 2):S51-S55.
2. Van Meter F, Gallo JW, Garcia-Rojas G, et al. A study of oral candidiasis in HIV-positive patients. J Dent Hyg. 1994;68: 30-34.
3. Klein RS, Harris CA, Butkus Small C, et al. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. NEJM. 1984; 311:354-358.
4. Lifson AR, Hilton JF, Westenhouse JL, et al. Time from HIV seroconversion to oral candidiasis or hairy leukoplakia among homosexual and bisexual men enrolled in three prospective cohorts. AIDS. 1994;8: 73-79.
5. Koletar SL, Russell JA, Fass RJ, Plouffe JF. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients with human immunodeficiency virus. Antimicrob Agents Chemother. 1990;34:2267-2268.
6. Pons V, Greenspan D, Debruin M, and the Multicenter Study Group. Therapy for oropharyngeal candidiasis in HIV-infected patients: A randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. J Acquired Immune Defic Syndr. 1993;6:1311-1316.
7. Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med. 1994;97:339-346.
8. De Wit S, Goossens H, Weerts D, Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet. 1989;1:746-748.
9. Cleary JD, Taylor JW, Chapman SW. Itraconazole in antifungal therapy. Ann Pharmacother. 1992;26:502-509.
10. Lake-Bakaar G, Tom W, Lake-Bakaar D, et al. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988;109:471-473.
11. Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis. 1993;17:1018-1021.
12. Goff DA, Koletar SL, Buesching WJ, et al. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin Infect Dis. 1995; 20:77-83.
13. Newman SL, Flanigan TP, Fisher A, et al. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis. 1994; 19:684-686.
14. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995;39:1-8.
15. Hay RJ, Dupont B, Graybill JR. First international symposium on itraconazole: A summary. Rev Infect Dis. 1987;9(Suppl 1):S1-S3.
16. Barchiesi F, Colombo AL, McGough DA, et al. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1994;38:1530-1533.
17. Blatchford NR. Treatment of oral candidosis with itraconazole: A review. J Am Acad Dermatol. 1990;23:565-567.
18. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother. 1993;37:778-784.
19. Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother. 1988;32:1310-1313.
20. Smith DE, Midgley J, Allan M, et al. Itraconazole versus ketoconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV. AIDS. 1991; 5:1367-1371.
21. Hostetler JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother. 1992;36:477-480.
22. Barone JA, Moskovitz BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole (ITR) solution compared with capsules in healthy volunteers. Presented at the Annual Meeting of the American College of Clinical Pharmacy; April 6-9, 1997; Panama City, Florida.
23. Desmet P, Kayembe K, Stoffels P, et al. Treatment of oral candidosis in AIDS patients with itraconazole oral solution. Presented at the Third Symposium, Topics in Mycology: Mycoses in AIDS Patients; November 20-23, 1989; Paris, France.
24. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NEJM. 1995;332:700-705.